

23rd July, 2026

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Symbol: CIPLA

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Press Release

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release dated 23rd July, 2026.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Encl: As above

Prepared by: Simona Dsouza

Q1 FY27 Results

One India Delivered Highest-ever quarterly Revenue with further Growth Acceleration

	Income from Operations	EBITDA	PAT
Q1 FY27:	INR 7,119 Cr	INR 1,192 Cr (16.7%)	INR 789 Cr (11.1%)

Mumbai, July 23, 2026: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its unaudited consolidated financial results for the quarter ended June 30th, 2026.

Key Highlights for the Quarter

- **One-India:** The business recorded highest quarterly sales with a solid growth of 12% YoY. Overall Chronic mix improved to 60.4% in the market#.
- **North America:** Delivered quarterly revenue of \$ 162 Mn.
- **One Africa:** Prescription business ranked No. 2 in the market*.
- **Emerging Markets and Europe:** Delivered quarterly revenue above \$100Mn+, recording a 5% YoY growth in USD terms.
- **R&D investments:** Stood at INR 486 Cr, accounting for 6.8% of sales, up 12.3% YoY, driven by increased product filings and development initiatives.
- **Strong net cash:** Net cash position of INR 9,494 Cr; Debt primarily includes lease liabilities and working capital requirements.

#Market data as per IQVIA MAT June '26 *Market data as per IQVIA MAT May '26

"We are pleased to share that we continue to make considerable progress across our focused markets. In Q1FY27, we delivered global revenues of INR 7,119 Cr. Our One-India business grew at solid 12% YoY. Branded Prescription business delivered a robust growth, with key therapies outpacing the market, Trade Generics recorded healthy growth and Anchor brands of Consumer Health Business maintained leadership position. The US business posted a revenue of \$ 162 Mn during the quarter. We expect continued sequential growth in North America, supported by upcoming product pipeline. South Africa private business continued to grow faster than the market. Emerging Markets and Europe continued its growth trajectory with revenue growth of 5% YoY in USD terms on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front."

Achin Gupta
MD and Global CEO, Cipla Ltd

For Queries Contact:

Corporate Communications
Heena Kanal
CorpComm@cipla.com

Investor Relations
Diksha Maheshwari
Investor.Relations@cipla.com

Cipla Ltd.
Cipla House,
Peninsula Business Park,
Ganpatrao Kadam Marg,
Lower Parel, Mumbai-400013

Market Updates

❖ One India Business

Branded Prescription:

Delivered market[#] growth of 15.4%, 183 bps higher than IPM. Key therapies like Respiratory, Urology, Cardiac and Anti-diabetes grew at strong double-digit market[#] growth, with the overall Chronic mix being improved to 60.4%.

Trade Generics:

The business recorded a healthy growth YoY. The performance was supported by execution excellence in distribution and new introductions. The business launched 3 new products during the quarter.

Consumer Health:

Anchor brands of Nicotex, Omnigel and Cipladine maintained leadership positions in their respective market segments.

❖ North America

Delivered quarterly revenue of \$ 162 Mn. Albuterol ranked No. 1 in the overall U.S. Albuterol MDI market, with a 21% market share*. During the quarter, the business launched gVentolin following regulatory approval received last quarter, with commercial shipments commenced and volumes expected to increase gradually as supply ramps up. This was complemented with launch of Nintedanib and Dapagliflozin, expanding our presence in high-growth therapy areas.

❖ One Africa

In South Africa Private Market secondary growth was at 6.5% versus the market** growth of 5.7%. The prescription business maintained its No.2 position.

❖ Emerging Markets and Europe

Deep market focus strategy in Emerging Markets and Europe has laid a solid foundation, with the business delivering a growth of 5% YoY in USD terms with an uptick in both DTM and B2B categories, along with sustained overall margins.

[#]Market data as per IQVIA, Quarter ended June 2026 | ^{*}Market data as per IQVIA week ending 26th June'26 | ^{**} Market data as per IQVIA MAT May'26

QUARTERLY BUSINESS WISE SALES PERFORMANCE

Business (In INR Cr)	Q1FY27	Q1FY26	Y-o-Y Growth
India (Rx + Gx + CHL [^])	3,452	3,070	12%
North America	1,532	1,933	-21%
One Africa [#]	977	871	12%
South Africa	658	695	-5%
Emerging Markets and Europe	999	861	16%
API and Others	160	222	-28%
Total	7,119	6,957	2%

[^] CHL – Cipla Health limited | [#] Includes South Africa, North Africa, Sub-Saharan Africa and Cipla Global Access

CONSOLIDATED PROFIT & LOSS STATEMENT

In INR Cr	Q1FY27	Q1FY26
Total Income from Operations	7,119	6,957
EBITDA	1,192	1,778
% of Income from Operations	16.7%	25.6%
PAT	789	1,298

BALANCE SHEET

Key Balance Sheet Items (INR Cr)	June-26	June-25
Equity	34,443	32,665
Total Debt [†]	600	459
Inventory	6,714	6,091
Cash and Cash Equivalents*	10,094	10,838
Trade Receivables	5,948	6,254
Trade Payables	3,446	3,093
Net Tangible Assets	7,889	6,669
Goodwill and Intangibles	6,928	5,138

[†]Total debt includes lease liabilities and borrowings | * Cash & cash equivalents include current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances

Announcement

Cipla to release Q1FY27 unaudited Financial Results on July 23, 2026

Date: July 23, 2026

- **1600 hrs IST – EARNINGS CONFERENCE CALL**

The Company will host an earnings conference call at 1600 hrs IST (1830 hrs SST/HKT, 1030 hrs GMT, 0530 hrs US ET), during which the leadership team will discuss financial performance and take questions. A transcript of the conference call will be available at www.cipla.com.

Earnings Conference Call Dial-in Information

Date and Time	July 23, 2026 at 1600 – 1700 hrs IST 1830 – 1930 hrs SST/HKT 1030 – 1130 hrs GMT 0530 – 0630 hrs US ET
Dial-in Numbers	
Universal Access	Primary Access: (+91 22 6280 1562) (+91 22 7115 8387)
Diamond pass link	Click here to register
Toll Free Number	USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045

ABOUT CIPLA LTD

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT June'26), 2nd Largest in the pharma prescription market in South Africa (IQVIA MAT May'26), and 2nd largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT June'26). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

Disclaimer: Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks. Cipla Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.